Eurofarma Innovation and Growth Strategy
15
15
HIGHEST MARKET SHARE IN NEW RELEASES
Unique Pipeline for the Near Future
Market Share of Released Products
Launches by Brazilian pharma in the last 24 months
Eurofarma's Portfolio Renewal Index
Released products in the past 24 months as a % of total portfolio
eurofarma
eurofarma
8.8%
13.7%
GRUPO NC
Hypera
pharma
achē
6.7%
11.6% 11.5%
9.9% 10.0% 10.2% 10.5%
10.1%
5.5%
8.9%
4.6%
-30% of revenue
8.4%
2.3%
APSEN
FARMACEUTICA
biolab
from launches of last 5
years
2.2%
-15% of revenue
FQM
1.9%
1.5%
from launches of last 3
years
2014
2015
2016
2017
2018
2019
2020
2021
1Q22
2Q22
Libbs
Highest Efficiency in the Development and Release
# of released products between 2017-2021
Current Innovation Pipeline
# and R$ million
2,781
3,664
4,545
5,343
164
322
868
1,093
689
133
65
117
441
4
361
371
346
48
43
269 63
258
3
3
47 43
40
05
224
199
35 34
50
25
50
19
18
149
42
38
0
15
0
9
15
eurofarma achē GRUPO NC biolab
CRISTALIA Hypera NOVARTIS Libbs SANOFI→
11
5- -3
15
1-0
7
3
8
TEUTO
Average days to release
# of released products
2022
2023
2024
Licenses
Prototype list
2025
Development list
2026
2027
2028
Expected RevenueView entire presentation